【摘要】：目的:觀察化痰解毒方聯(lián)合分子靶向藥物治療晚期非小細(xì)胞肺癌患者的近期療效、生活質(zhì)量變化及毒副反應(yīng)情況等,以評價中醫(yī)藥在晚期非小細(xì)胞肺癌治療中的作用與優(yōu)勢。方法:選取2013年1月至2014年12月新疆維吾爾自治區(qū)中醫(yī)醫(yī)院腫瘤科病房及門診經(jīng)治的IIIb期或IV期非小細(xì)胞肺癌患者63例,隨機分配至治療組32例,對照組31例,治療組采用化痰解毒方聯(lián)合分子靶向藥物(厄洛替尼、吉非替尼或者�？颂婺崞渲兄�),對照組采用單純靶向治療(厄洛替尼、吉非替尼或者�？颂婺崞渲兄�),治療1月評估療效。結(jié)果:①治療組與對照組的有效率為18.75%和12.90%(P=0.525),無統(tǒng)計學(xué)意義;治療組與對照組的疾病控制率為75.00%和77.42%(P=0.946),無統(tǒng)計學(xué)意義。②治療組與對照組治療前后患者的中醫(yī)證候積分,經(jīng)統(tǒng)計學(xué)檢驗,P0.05,有統(tǒng)計學(xué)差異;治療組與對照組治療前后患者的KPS評分,經(jīng)統(tǒng)計學(xué)檢驗,P0.05,有統(tǒng)計學(xué)差異。③治療組在皮疹、消化道反應(yīng)、轉(zhuǎn)氨酶升高等毒副反應(yīng)及安全性方面較對照組發(fā)生率小。結(jié)論:化痰解毒方聯(lián)合靶向治療可有效緩解靶向治療毒副反應(yīng),改善患者臨床癥狀,提高患者生活質(zhì)量,起到減毒增效的作用。
[Abstract]:Objective: to observe the short-term efficacy, quality of life (QOL) and side effects of Huatan Jiedu recipe combined with molecular targeted drugs in the treatment of advanced non-small cell lung cancer (NSCLC), so as to evaluate the role and advantages of traditional Chinese medicine (TCM) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: from January 2013 to December 2014, 63 patients with IIIb or IV stage non-small cell lung cancer in oncology department and outpatient department of Xinjiang Uygur Autonomous region Hospital of traditional Chinese Medicine were randomly assigned to the treatment group (32 cases) and the control group (31 cases). The treatment group was treated with Huatan jiedu recipe combined with molecular targeting drugs (alotinib, gefitinib or one of the ectene), while the control group was treated with only targeted therapy (erlotinib. Gefitinib or one of the actinis), evaluated the efficacy of one month of treatment. Results: 1the effective rates of the treatment group and the control group were 18.75% and 12.90% (P 鈮，

本文編號：2506063